AlphAIAlphAI — Financial news for AI agents
thepharmaletter.comOCT 133 min read$REGN

Regeneron presents new long-term data for Pasatru

Regeneron Pharmaceuticals (Nasdaq: REGN) reported 84-week Phase III trial results for Pasatru (garetosmab-grts) in treating fibrodysplasia ossificans progressiva (FOP). The data showed sustained efficacy in stopping new bone growth and reducing flare-ups. REGN shares closed up 2.2% at $762.81 after the announcement. The findings were presented at the ASBMR Annual Meeting.

Original reporting
thepharmaletter.com
Published Oct 13, 2026, 9:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 12:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Regeneron presents new long-term data for Pasatru — source image
Source · thepharmaletter.com
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

The longer-term 84-week results are framed as sustained efficacy in halting rogue bone growth and reducing flare-ups, which can strengthen the probability of future regulatory success and improve risk perception for Pasatru.

02

Market read

A positive long-term Phase III readout is a tangible catalyst for REGN and can support near-term momentum, especially given the same-day share gain reported.

03

What to watch

Conference presentation format can delay full data availability; traders may wait for a full poster, dataset, or filing timeline before extending positions.

Relevance 7/10Novelty 6/10Timing: after-hours or next-session positioning following the OPTIMA 84-week data announcement

Background

The OPTIMA Phase III trial is evaluating Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP), a rare disease where durable suppression of new bone growth is a key efficacy goal.

Company-level read

Ticker impact

$REGNBullishMedium confidence
Context

Regeneron reported positive 84-week Phase III OPTIMA results for Pasatru (garetosmab-grts), with shares closing up 2.2% after the announcement.

Expected impact

Likely upward bias as traders price in durability of efficacy and reduced flare-ups, though magnitude may be capped until regulatory next steps are clarified.

Evidence & confidence

The article cites positive 84-week outcomes and a same-day share rise, but provides no regulatory filing timing or new endpoints beyond the longer-term readout.

Market effects

Sector

Reinforces investor appetite for rare-disease biotech with durable Phase III efficacy, potentially improving sentiment for peers in musculoskeletal/rare immunology pathways.

Regional

Limited, primarily US biotech sentiment given the Nasdaq-listed issuer and US conference venue.

Global

Moderate, as ASBMR late-breaking data can influence global rare-disease trial expectations, but no cross-border regulatory action is mentioned.

Counterpoint

What could challenge this read

Without details on regulatory plans, primary endpoint definitions, or effect sizes, the market may treat the 84-week update as incremental rather than a decisive catalyst.

Key entities

  • company
    Regeneron Pharmaceuticals

    US biotech major announcing positive 84-week OPTIMA Phase III results for Pasatru.

  • drug
    Pasatru (garetosmab-grts)

    Regeneron’s investigational therapy evaluated in the OPTIMA Phase III trial for FOP.

  • clinical_trial
    OPTIMA trial

    Phase III study assessing Pasatru efficacy and durability over 84 weeks.

  • conference
    ASBMR Annual Meeting

    Venue where the late-breaking oral session presented the longer-term data.

Read at source← All news

StoryRegeneron reports durable 84-week Pasatru results in adult FOP trial

Also covered by

5 outlets

Related articles

OCT 13
$REGNMedAI 9/10

Regeneron reports 84-week Phase III data for Pasatru in adult FOP

Regeneron Pharmaceuticals reported 84-week Phase III trial data for Pasatru in adults with fibrodysplasia ossificans progressiva (FOP). The trial showed Pasatru prevented new heterotopic ossification lesions and reduced flare-ups compared to placebo. Safety data remained consistent, with no deaths reported. Regulatory submissions are planned in several countries, including Japan.

finance.yahoo.com2 min
OCT 13
$REGNHigh

Regeneron Reports Zero New Bone Lesions Through Week 84 In Pasatru FOP Trial

Regeneron (REGN) reported 84-week data from the Phase 3 OPTIMA trial, showing Pasatru prevented new HO lesions in FOP patients. The trial met primary endpoints, with no new lesions from Week 56 to 84. Pasatru also reduced flare-ups and had a well-tolerated safety profile. REGN plans to start a Phase 3 study in children with FOP. REGN stock closed at $762.81, up 2.18%.

rttnews.com2 min
OCT 12
Med

Regeneron Pharmaceuticals, Inc. Announces Positive 84-Week Results From Phase 3 OPTIMA Trial Evaluating Pasatru In Adults With Fibrodysplasia Ossificans Progressiva

Regeneron announced 84-week results from its Phase 3 OPTIMA trial for Pasatru in adults with FOP, showing sustained efficacy in halting new bone growth and reducing flare-ups. The trial met its primary endpoint at 56 weeks and maintained results at 84 weeks. Pasatru was recently FDA-approved based on 56-week data. Regeneron plans to start a Phase 3 trial for adolescents and children with FOP later this year.

marketscreener.com2 min
OCT 12
$REGNMed

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month

Regeneron (REGN) reported positive long-term results for its rare disease drug Pasatru, showing no new abnormal bone growth in an extended Phase 3 trial. The trial enrolled 63 adults, with zero new lesions in the Pasatru group compared to nine in the placebo group. REGN shares rose 2.8%, their best day in over a month. BofA raised its price target to $908, implying 19% upside. The company plans a new study for children and adolescents later this year.

finance.yahoo.com5 min
OCT 12
$REGNHigh

Regeneron (REGN) Reports Positive 84-Week OPTIMA Trial Results f

Regeneron (REGN) reported 84-week OPTIMA trial results, showing Pasatru's sustained efficacy in treating fibrodysplasia ossificans progressiva (FOP). The drug prevented new bone formation and reduced flare-ups. REGN is modestly undervalued with a GF Value of $918.21 vs. current price of $766.06, offering a 16.6% margin of safety. The company has a GF Score of 87/100, indicating strong financial health and valuation appeal.

gurufocus.com2 min
OCT 12
$REGNMed

Regeneron reports sustained efficacy for FOP treatment Pasatru

Regeneron Pharmaceuticals reported 84-week trial data for Pasatru, showing sustained efficacy in treating fibrodysplasia ossificans progressiva. Compared to placebo, Pasatru had fewer new lesions and flare-ups. Common side effects included acne and epistaxis. The FDA approved Pasatru based on 56-week data, and a regulatory review is ongoing in Europe. Regeneron plans a Phase 3 trial in younger patients later this year.

investing.com4 min